Modification of inherent and drug-induced dopaminergic activity after exposure to benzo(α)pyrene

被引:22
作者
Konstandi, Maria [1 ]
Harkitis, Panagiotis
Thermos, Kyriaki
Ogren, Sven Ove
Johnson, Elizabeth O.
Tzimas, Panagiotis
Marselos, Marios
机构
[1] Univ Ioannina, Sch Med, Dept Pharmacol, GR-45110 Ioannina, Greece
[2] Univ Crete, Sch Med, Dept Basic Sci, Pharmacol Lab, Iraklion, Greece
[3] Karolinska Inst, Dept Neurosci, Sect Behav Neurosci, S-17177 Stockholm, Sweden
[4] Univ Ioannina, Sch Med, Dept Anat, GR-45110 Ioannina, Greece
关键词
dopamine; D-2-receptors; brain; Benzo(alpha)pyrene; rat;
D O I
10.1016/j.neuro.2007.04.007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The aim of this study was to investigate the effect of benzo(alpha)pyrene (B(alpha)P), a representative polycyclic aromatic hydrocarbon (PAH), on dopaminergic activity in brain. (B(alpha)P) altered dopaminergic activity in discrete regions of the rat brain, including the hippocampus, hypothalamus, caudate putamen and nucleus accumbens. Specifically, B(alpha)P increased DA levels in the hippocampus and DA turnover in the caudate putamen. In addition, B(alpha)P suppressed DA levels in the caudate putamen and DA turnover in the nucleus accurnbens. B(alpha)P also altered the effect of several dopaminergic agents, L-DOPA, sulpiride and bromocriptine, on DA activity. In particular, B(alpha)P enhanced the L-DOPA-induced increase in the DA turnover ratio in the caudate putamen and increased DA levels in the nucleus accumbens. B(alpha)P also reversed the sulpiride-induced increase of DA turnover in the nucleus accumbens and the bromocriptine-induced increase of DA turnover in the hippocampus. In addition, DA turnover was increased by B(alpha)P in the nucleus accumbens and caudate putamen and DA levels were suppressed in the nucleus accumbens of bromocriptine treated rats, though the drug alone had no effect. These changes indicate that exposure to B(alpha)P and related compounds may affect dopaminergic function in discrete brain regions that are implicated in cognitive functions, psychosis, depression and Parkinson's disease, and may possibly interfere with their pharmacological intervention. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:860 / 867
页数:8
相关论文
共 58 条
[1]   Lifestyle-related risk factors for Parkinson's disease: a population-based study [J].
Baldereschi, M ;
Di Carlo, A ;
Vanni, P ;
Ghetti, A ;
Carbonin, P ;
Amaducci, L ;
Inzitari, D .
ACTA NEUROLOGICA SCANDINAVICA, 2003, 108 (04) :239-244
[2]   6-YEAR RESULTS OF TREATMENT WITH LEVODOPA PLUS BENZERAZIDE IN PARKINSONS-DISEASE [J].
BARBEAU, A ;
ROY, M .
NEUROLOGY, 1976, 26 (05) :399-404
[3]   DECLINE IN LIVER NEOPLASMS IN WILD BROWN BULLHEAD CATFISH AFTER COKING PLANT CLOSES AND ENVIRONMENTAL PAHS PLUMMET [J].
BAUMANN, PC ;
HARSHBARGER, JC .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1995, 103 (02) :168-170
[4]   CHANGES IN DOPAMINE-D1, DOPAMINE-D2 AND DOPAMINE-D3 RECEPTOR MESSENGER-RNA LEVELS IN RAT-BRAIN FOLLOWING ANTIPSYCHOTIC TREATMENT [J].
BUCKLAND, PR ;
ODONOVAN, MC ;
MCGUFFIN, P .
PSYCHOPHARMACOLOGY, 1992, 106 (04) :479-483
[5]   THE EFFECTS OF HIGH-LEVELS OF POLYCYCLIC AROMATIC-HYDROCARBONS ON SEDIMENT PHYSICOCHEMICAL PROPERTIES AND BENTHIC ORGANISMS IN A POLLUTED STREAM [J].
CATALLO, WJ ;
GAMBRELL, RP .
CHEMOSPHERE, 1987, 16 (05) :1053-1063
[6]  
Cooper JR, 1996, BIOCH BASIS NEUROPHA, P293
[7]   Monoamines (norepinephrine, dopamine, serotonin) in the rat medial vestibular nucleus: Endogenous levels and turnover [J].
Cransac, H ;
CottetEmard, JM ;
Pequignot, JM ;
Peyrin, L .
JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (04) :391-401
[8]   Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease [J].
De Reuck, J ;
De Weweire, M ;
Van Maele, G ;
Santens, P .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 231 (1-2) :35-39
[9]   INVIVO RELEASE OF DOPAMINE AND ITS METABOLITES FOLLOWING A DIRECT INFUSION OF L-DOPA INTO THE CAUDATE-NUCLEUS OF AWAKE, FREELY BEHAVING RATS USING A PUSH-PULL CANNULA [J].
DLUZEN, DE ;
RAMIREZ, VD .
NEUROSCIENCE LETTERS, 1987, 82 (01) :29-34
[10]  
ELGEMAYEL G, 1986, J PHARM PHARMACOL, V38, P691